Harbin Jixianglong Biotech Co., Ltd. vs Philips North America: FDA Enforcement Comparison

Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 1 for Harbin Jixianglong Biotech Co., Ltd..

Harbin Jixianglong Biotech Co., Ltd.: 1 warning letter, 0 recalls, 0 approval records, 0 Form 483s.

Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.

Side by side

Harbin Jixianglong Biotech Co., Ltd. — Warning letters1

Philips North America — Warning letters0

Harbin Jixianglong Biotech Co., Ltd. — Recalls0

Philips North America — Recalls355

Harbin Jixianglong Biotech Co., Ltd. — Approval records0

Philips North America — Approval records0

Harbin Jixianglong Biotech Co., Ltd. — Form 483s0

Philips North America — Form 483s0

Timeline

Harbin Jixianglong Biotech Co., Ltd.

Most recent FDA action: May 1, 2026

Full history →

Philips North America

Most recent FDA action: July 1, 2026

Full history →

Cite this comparison

Pre-formatted for a story, footnote, or reference list:

"Harbin Jixianglong Biotech Co., Ltd. vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed August 27, 2026. https://argushq.ai/compare/harbin-jixianglong-biotech-co-ltd-vs-philips-north-america

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗